HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

In this episode of HOPA Now, Dr. Allison Baxley covers some of the most important clinical topics in the treatment of gastrointestinal cancers. She covers treatment recommendations and updates for colorectal cancer, pancreatic cancer, landmark trials in esophageal and gastric cancer, and hepatocellular carcinoma.

In this episode, you will learn:

Gastrointestinal Cancers: Top 10 Clinical Pearls

• A review of the landmark MOSAIC clinical trial and its subsequent recommendations
• An outline of the treatment paradigm of rectal cancer and its chemotherapy, surgery, and radiation treatment options
• Molecular markers that are relevant in metastatic colon cancer and their effect on the choice of biologic agents
• Primary tumor location in metastatic colorectal cancer and its influence on certain biologic agents
• An overview of three landmark studies concerning adjuvant treatment options for pancreatic cancer patients
• The standard first-line options for metastatic treatment of pancreatic cancer
• The unique role of pharmacists in the unique supportive care needs of pancreatic cancer patients
• Landmark trials in esophageal and gastric cancer and drug regimen recommendations
• An overview of recent findings and recommendations regarding hepatocellular carcinoma

Mentioned in This Episode:

HOPA

Quotes:

“This trial showed us that certain stage two patients don’t benefit from adjuvant chemotherapy at all.” — Dr. Allison Baxley

“All patients with metastatic colorectal cancer should be tested for K-Ras, N-Ras, and B-Ras status.” — Dr. Allison Baxley

“It’s clear that colon tumors have different molecular characteristics depending on where they arise.”  — Dr. Allison Baxley

“Nearly all pancreatic cancer patients also require some degree of pancreatic enzyme replacement due to either their disease or surgery.” — Dr. Allison Baxley